Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one
million people die annually from HBV-related causes, including liver cancer. Although there …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Hepatitis B protein x (HBx) has been reported to promote tumorigenesis in hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC), but the mechanism awaits further …

Objective Therapeutic strategies silencing and reducing the hepatitis B virus (HBV)
reservoir, the covalently closed circular DNA (cccDNA), have the potential to cure chronic …

Background & Aims HBeAg seroconversion during the natural history of chronic hepatitis B
(CHB) is associated with a strong drop in serum HBV DNA levels and a reduction of …

Phase separation regulates fundamental processes in gene expression and is mediated by
the local concentration of proteins and nucleic acids, as well as nucleic acid secondary …

Summary Hepatitis B virus (HBV) DNA integration–originally recognised as a non-functional
byproduct of the HBV life cycle–has now been accepted as a significant contributor to HBV …

RNA stability and quality control are integral parts of gene expression regulation. A key
factor shaping eukaryotic transcriptomes, mainly via 3′–5′ exoribonucleolytic trimming or …

Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used,
over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require …

HBV is an enveloped DNA virus that replicates its DNA genome via reverse transcription of a
pregenomic (pg) RNA intermediate in hepatocytes. Interestingly, HBV RNA can be detected …